Use of nonnucleoside reverse-transcriptase inhibitors

American Journal of Health-System Pharmacy

Volumn 55, Issue 3, 1998, Pages 283-287

  Holtzer, Christopher D ^a,b   Coleman, Rebecca L ^b,c  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTICONVULSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DELAVIRDINE; EFAVIRENZ; HISTAMINE H2 RECEPTOR ANTAGONIST; METHADONE; NEVIRAPINE; ORAL CONTRACEPTIVE AGENT; PROTEINASE INHIBITOR; RIFABUTIN; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; THEOPHYLLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

ANTIVIRAL ACTIVITY; COMBINATION CHEMOTHERAPY; DRUG ANTAGONISM; DRUG INFORMATION; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG USE; ENZYME INHIBITION; FATIGUE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NAUSEA; PHARMACODYNAMICS; PRIORITY JOURNAL; RASH; REVIEW; STEVENS JOHNSON SYNDROME;

EID: 0032005238     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/55.3.283     Document Type: Review

References (30)

1. Carpenter CC, Fischl M, Hammer SM et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA Panel. JAMA. 277:1962-9.
2. Panel on Clinical Practices of HIV Infection, Department of Health and Human Services, Henry J. Kaiser Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescence. Fed Regist. 1997; 62(Nov 5):1-44.
3. Merluzzi VJ, Hargrave KD, Labadia M et al. Inhibition of HIV-1 replication by a non-nucleoside reverse-transcriptase inhibitor. Science. 1990; 250:1411-3.
4. Dueweke TJ, Kezdy FJ, Waszak MR et al. The binding of a novel bisheteroarylpiperazine mediates inhibition of human immunodeficiency virus type 1 reverse transcriptase. J Biol Chem. 1992; 267:27-30.
5. Grob PM, Wu JC, Cohen KA et al. Nonnucleoside inhibitors of HIV-1 reverse-transcriptase: nevirapine as a prototype drug. AIDS Res Hum Retroviruses. 1992; 8:145-52.
6. Havlir D, Cheeseman SH, McLaughlin M et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effects in patients with human immunodeficiency virus infections. J Infect Dis. 1995; 171:537-45.
7. Rescriptor package insert. Kalamazoo, MI: Pharmacia & Upjohn; 1997.
8. Viramune package insert. Columbus, OH: Roxane Laboratories; 1996.
9. Yazdanian M, Ratigan S, Joseph D et al. Nevirapine, a nonnucleoside RT inhibitor, readily permeates the blood brain barrier. Paper presented at Conference on Retroviruses and Opportunistic Infections. Washington, DC; 1997 Jan 22-26.
10. Richman DD, Havlir D, Corbeil J et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol. 1994; 68:1660-6.
11. Zhu QY, Scarborough A, Polsky B et al. Drug combinations and effect parameters of zidovudine, stavudine and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains. AIDS Res Hum Retroviruses, 1996; 12:507-17.
12. Koup RA, Brester R, Grob R et al. Nevirapine synergistically inhibits HIV-1 replication in combination with zidovudine, interferon and CD4 immunoadhesion. AIDS. 1993; 7:1181-4.
13. Richman D, Shin CK, LowryJ et al. Human immunodeficiency virus type I mutants resistant to nonnucleoside inhibitors of reverse-transcriptase arise in tissue culture. Proc Natl Acad Sci U S A. 1991; 88:11241-5.
14. D'Aquila RT, Hughes MD, Johnson VA et al. Nevirapine, zidovudine and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1996; 124:1019-30.
15. 3. Paper presented at International Conference on AIDS. Vancouver, Canada; 1996 Jul 7-12.
16. Kohlbrenner V, Dransfield K, Cotton D et al. Cutaneous eruptions associated with nevirapine (NVP) therapy in HIV-1 infected individuals. Paper presented at International Conference on AIDS. Vancouver, Canada; 1996 Jul 7-12.
17. Murphy R, Gagnier P, Lamson M et al. Effect of nevirapine (NVP) on pharmacokinetics (PK) of indinavir (IDV) and ritonavir (RTV) in HIV-1 patients. Paper presented at Conference on Retroviruses and Opportunistic Infections. Washington, DC; 1997 Jan 22-26.
18. Sahai J, Cameron W, Salgo M et al. Drug interaction between saquinavir (SQV) and nevirapine (NVP). Paper presented at Conference on Retroviruses and Opportunistic Infections. Washington, DC; 1997 Jan 22-26.
19. Dueweke TJ, Poppe SM, Romero DL et al. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replica tion. Antimicrob Agents Chemother. 1993; 37:1127-31.
20. Chong KT, Pagano PJ. Synergistic inhibition of human immunodeficiency type 1 replication in vitro by two and three-drug combinations of delavirdine, lamivudine and zidovudine. Paper presented at International Conference on AIDS. Vancouver, Canada; 1996 Jul 7-12.
21. Dueweke TJ, Pushkarskaya T, Polle SM et al. A mutation in reverse transcriptase of bis(heteroaryl)piperazine resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc Natl Acad Sci U S A. 1993; 90:4713-7.
22. Friedland GH, Fischl MA, Poaard RB et al. Delavirdine mesylate (DLV) in two and three drug combinations with zidovudine (ZDV) and didanosine (ddI), (ACTG 261). Paper presented at meeting of Infectious Diseases Society of America. San Francisco, CA; 1997 Sep 13-16.
23. Davey RT, Chaitt DG, Reed GF et al. Randomized, controlled Phase I/II trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother. 1996; 40:1657-64.
24. Cox SR, Ferry JJ, Batts DH et al. Delavirdine and marketed protease inhibitors (PIs): pharmacokinetic (PK) interaction studies in healthy volunteers. Paper presented at Conference on Retroviruses and Opportunistic Infections. Washington, DC; 1997 Jan 22-26.
25. Bacheler LT, Anton E, Baker D et al. Impact of mutation, plasma protein binding and pharmacokinetics on clinical efficacy of the HIV-1 non-nucleoside reverse transcriptase inhibitor, DMP-266. Paper presented at Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada; 1997 Sep 28-Oct 1.
26. Kahn J, Havlir D, Mayers D et al. Long-term (50 weeks) anti-HIV-1 activity and tolerability (24 weeks) of DMP-266 in combination with indinavir (IDV) [DMP-266-003, cohort III]. Paper presented at meeting of Infectious Diseases Society of America. San Francisco, CA; 1997 Sep 13-16.
27. Fiske WD, Nibbelink DW, Brennan JM et al. DMP-266 cerebral-spinal fluid concentrations (CSF) after oral administration. Paper presented at Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada; 1997 Sep 28-Oct 1.
28. Fiske WD, Benedek IH, White SJ et al. Pharmacokinetic interaction between DMP-266 and nelfinavir mesylate (NFV) in healthy volunteers. Paper presented at Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada; 1997 Sep 28-Oct 1.
29. Bacheler LT, George H, Ambremski K et al. Mutations associated with viral load rebound In patients treated with the HIV-1 non-nucleoside reverse transcriptase inhibitor DMP-266 in combination with the HIV-1 protease inhibitor Crixivan. Paper presented at Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada; 1997 Sep 28-Oct 1.
30. Riddler S, Stein D, Mayers D. Durable clinical anti-HIV-1 activity (48 weeks) and tolerability (24 weeks) for DMP-266 in combination with indinavir (IDV) [DMP-266-003, Cohort IV]. Paper presented at meeting of Infectious Diseases Society of America. San Francisco, CA; 1997 Sep 1316.